about
Interleukin-17 cytokine signalling in patients with asthmaBronchodilation by pituitary adenylate cyclase-activating peptide and related peptides.Airway neutrophils and interleukin-17.Interleukin-17A during local and systemic Staphylococcus aureus-induced arthritis in mice.Free, soluble interleukin-17 protein during severe inflammation in human airways.Neutrophilic airway inflammation and IL-17.Different effects of salmeterol, formoterol and salbutamol on cholinergic responses in the ferret trachea.Increase in net activity of serine proteinases but not gelatinases after local endotoxin exposure in the peripheral airways of healthy subjectsComorbidity and health-related quality of life in patients with severe chronic obstructive pulmonary disease attending Swedish secondary care unitsBronchodilatation in vivo by carbon monoxide, a cyclic GMP related messengerIL-17-induced cytokine release in human bronchial epithelial cells in vitro: role of mitogen-activated protein (MAP) kinasesSystemic cytokine signaling via IL-17 in smokers with obstructive pulmonary disease: a link to bacterial colonization?Rationale for targeting interleukin-17 in the lungs.Systemic signs of neutrophil mobilization during clinically stable periods and during exacerbations in smokers with obstructive pulmonary disease.Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism.Interleukin-17 and airway remodelling.Non-adrenergic, non-cholinergic neural activation in guinea-pig bronchi: powerful and frequency-dependent stabilizing effect on toneA role for the cytoplasmic adaptor protein Act1 in mediating IL-17 signaling.The IL-17 family of cytokines--applications in respiratory medicine and allergology.Interleukin-17 as a drug target in human disease.West Sweden Asthma Study: prevalence trends over the last 18 years argues no recent increase in asthma.Impact of IL-17 on cells of the monocyte lineage in health and disease.IL-17 in human asthma.IL-16 in the airways of lung allograft recipients with acute rejection or obliterative bronchiolitis.Interleukin-26: An Emerging Player in Host Defense and Inflammation.Pharmacological modulation of interleukin-17-induced GCP-2-, GRO-alpha- and interleukin-8 release in human bronchial epithelial cells.Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists.Functional type II VIP-PACAP receptors in human airway epithelial-like cells.NANC neural control of airway smooth muscle tone.Interleukin-26 in antibacterial host defense of human lungs. Effects on neutrophil mobilization.Inhibition of bronchoconstriction by pituitary adenylate cyclase activating polypeptide (PACAP 1-27) in guinea-pigs in vivo.Non-adrenergic, non-cholinergic neural activation stabilizes smooth-muscle tone independently of eicosanoid factors in guinea-pig isolated airways.Long-lasting smooth-muscle relaxation by a novel PACAP analogue in human bronchi.Increased matrix metalloproteinase-9 concentration and activity after stimulation with interleukin-17 in mouse airways.The cytokine interleukin-26 as a biomarker in pediatric asthma.Increased net gelatinase but not serine protease activity in bronchiolitis obliterans syndrome.Long lasting smooth muscle relaxation by a novel PACAP analogue in guinea-pig and primate airways in vitro.Tachykinins mediate the potentiation of antigen-induced bronchoconstriction by cold air in guinea pigs.Reduced late asthmatic response by repeated low-dose allergen exposure.Effect of seasonal allergen exposure on mucosal IL-16 and CD4+ cells in patients with allergic rhinitis.
P50
Q27004199-F6ECF59A-6C8B-4E11-A9E3-2DF60C010455Q33748969-CB0852C9-9B22-4A88-A09F-2207C885C767Q33942925-7DA34AC9-FA44-4E1D-BC37-7794FB02D7E5Q34119334-E9265ED0-D199-4C62-A1FC-4E6B504A75C3Q34122398-2C50E1A4-ED62-4833-BF84-43519A20557DQ34778056-F18C564C-26DA-4439-9FD1-D33E7AB7E73AQ34793042-AB8A55C1-B4C4-4A9C-AD67-E7729F94EA14Q35005349-3C288F5F-2103-4204-9E45-4AB2ECD16A9BQ35026147-75EB6C58-50B0-4A34-94F6-9CEBB47E4110Q35027725-A475F09A-1F47-4E33-A9A9-2954BBDC4DB5Q35043470-C5F0B0BD-42C0-4A59-8725-84355E94D802Q35240244-32578CA6-A90E-42FD-82A5-48D85CF85662Q35647104-DC37C804-90AC-4B49-9E25-1FBE5414D0DBQ35825949-B940C8CF-6710-4CB1-AAE2-EBAE16587CD8Q36280784-9C0A94BB-5C70-45A3-9C97-DAA0B7130089Q36312388-F2B457A8-4A01-4C40-A64A-9BD64FB854A8Q36329511-8A55BA8C-1638-4C32-8A0E-C2B83B13D287Q36904158-EBA28EC6-2B09-4282-8F16-19FD06C04F12Q37348142-D1879BFD-BB1C-48D4-931E-E05AFFA0B465Q37375323-87D7A110-232C-4B55-AE61-EA827EC8F330Q37411225-7D7460CC-3566-4786-B208-705A24F20BFDQ37516013-4968FBA6-4257-4A53-A585-825DE1284B4DQ37997818-7B64FFF4-D1F4-47DC-BFC2-C42D79A23F49Q38352445-C2F44237-A613-4579-AF76-3F92764AC304Q38552455-ED972A5C-F288-4A23-BD09-675C7738ADB3Q40670087-6A810991-4A9D-4877-AEFA-90836233DC6FQ41069825-8E9B29CF-B038-4E1A-AC8F-52C3A25A0AB6Q41138234-408B6351-29F5-4185-A1E0-3C1BDB748ED8Q41289610-E3D63C83-0BFB-4E48-8204-C71AD94BF326Q41712697-30DE1A42-90CA-4B6D-8022-45EB101859BAQ42039126-FE2B88D4-900C-4964-AC0F-249B9F446424Q42110969-12904D6D-4494-434F-AE30-8DEFC628ECCFQ42169987-A570923E-843C-4215-B064-4DD8B674D89FQ42264569-AC3DFE46-45C0-4FBE-AFB7-EFC9E2232639Q42924612-AB7596A0-4EA7-400E-95C0-71628B7A9E90Q43086732-30F9DCAD-9238-4C35-A366-811C947FB305Q43175514-D3D1A3C6-F5F7-4A8A-965E-EC079359A531Q43651529-3488746D-E610-443F-8581-1AAF30EB7A70Q43697570-3115A5CA-1E79-45A3-AF27-D13070E733C7Q43733451-896E3F70-150F-451E-B5BE-2A99371DCF1F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Anders Lindén
@ast
Anders Lindén
@en
Anders Lindén
@es
type
label
Anders Lindén
@ast
Anders Lindén
@en
Anders Lindén
@es
prefLabel
Anders Lindén
@ast
Anders Lindén
@en
Anders Lindén
@es
P106
P21
P31
P496
0000-0003-1258-2928